Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 195

1.

Cardiovascular Diseases And Psychiatric Disorders During The Diagnostic Workup Of Suspected Hematological Malignancy.

Liu Q, Andersson TM, Jöud A, Shen Q, Schelin ME, Magnusson PK, Smedby KE, Fang F.

Clin Epidemiol. 2019 Dec 2;11:1025-1034. doi: 10.2147/CLEP.S218063. eCollection 2019.

2.

Comorbidities and sex differences in causes of death among mantle cell lymphoma patients - A nationwide population-based cohort study.

Glimelius I, Smedby KE, Eloranta S, Jerkeman M, Weibull CE.

Br J Haematol. 2019 Nov 13. doi: 10.1111/bjh.16317. [Epub ahead of print]

PMID:
31721156
3.

Increased risk of multiple myeloma in primary Sjögren's syndrome is limited to individuals with Ro/SSA and La/SSB autoantibodies.

Mofors J, Björk A, Smedby KE, Kvarnström M, Forsblad-d'Elia H, Magnusson-Bucher S, Eriksson P, Mandl T, Baecklund E, Nordmark G, Wahren-Herlenius M.

Ann Rheum Dis. 2019 Nov 6. pii: annrheumdis-2019-216287. doi: 10.1136/annrheumdis-2019-216287. [Epub ahead of print] No abstract available.

PMID:
31694814
4.

Beta-Blocker Use and Lung Cancer Mortality in a Nationwide Cohort Study of Patients with Primary Non-Small Cell Lung Cancer.

Udumyan R, Montgomery S, Fang F, Valdimarsdottir U, Hardardottir H, Ekbom A, Smedby KE, Fall K.

Cancer Epidemiol Biomarkers Prev. 2019 Oct 22. doi: 10.1158/1055-9965.EPI-19-0710. [Epub ahead of print]

PMID:
31641010
5.

Evaluation of the antibody response to the EBV proteome in EBV-associated classical Hodgkin lymphoma.

Liu Z, Jarrett RF, Hjalgrim H, Proietti C, Chang ET, Smedby KE, Yu KJ, Lake A, Troy S, McAulay KA, Pfeiffer RM, Adami HO, Glimelius B, Melbye M, Hildesheim A, Doolan DL, Coghill AE.

Int J Cancer. 2019 Oct 16. doi: 10.1002/ijc.32741. [Epub ahead of print]

PMID:
31618442
6.

Inherited variants at 3q13.33 and 3p24.1 are associated with risk of diffuse large B-cell lymphoma and implicate immune pathways.

Kleinstern G, Yan H, Hildebrandt MAT, Vijai J, Berndt SI, Ghesquières H, McKay J, Wang SS, Nieters A, Ye Y, Monnereau A, Brooks-Wilson AR, Lan Q, Melbye M, Jackson RD, Teras LR, Purdue MP, Vajdic CM, Vermeulen RCH, Giles GG, Cocco PL, Birmann BM, Kraft P, Albanes D, Zeleniuch-Jacquotte A, Crouch S, Zhang Y, Sarangi V, Asmann Y, Offit K, Salles G, Wu X, Smedby KE, Skibola CF, Slager SL, Rothman N, Chanock SJ, Cerhan JR.

Hum Mol Genet. 2019 Oct 10. pii: ddz228. doi: 10.1093/hmg/ddz228. [Epub ahead of print]

PMID:
31600786
7.

Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes.

Din L, Sheikh M, Kosaraju N, Smedby KE, Bernatsky S, Berndt SI, Skibola CF, Nieters A, Wang S, McKay JD, Cocco P, Maynadié M, Foretová L, Staines A, Mack TM, de Sanjosé S, Vyse TJ, Padyukov L, Monnereau A, Arslan AA, Moore A, Brooks-Wilson AR, Novak AJ, Glimelius B, Birmann BM, Link BK, Stewart C, Vajdic CM, Haioun C, Magnani C, Conti DV, Cox DG, Casabonne D, Albanes D, Kane E, Roman E, Muzi G, Salles G, Giles GG, Adami HO, Ghesquières H, De Vivo I, Clavel J, Cerhan JR, Spinelli JJ, Hofmann J, Vijai J, Curtin K, Costenbader KH, Onel K, Offit K, Teras LR, Morton L, Conde L, Miligi L, Melbye M, Ennas MG, Liebow M, Purdue MP, Glenn M, Southey MC, Din M, Rothman N, Camp NJ, Wong Doo N, Becker N, Pradhan N, Bracci PM, Boffetta P, Vineis P, Brennan P, Kraft P, Lan Q, Severson RK, Vermeulen RCH, Milne RL, Kaaks R, Travis RC, Weinstein SJ, Chanock SJ, Ansell SM, Slager SL, Zheng T, Zhang Y, Benavente Y, Taub Z, Madireddy L, Gourraud PA, Oksenberg JR, Cozen W, Hjalgrim H, Khankhanian P.

Genet Epidemiol. 2019 Oct;43(7):844-863. doi: 10.1002/gepi.22242. Epub 2019 Aug 13.

PMID:
31407831
8.

A multivariable approach for risk markers from pooled molecular data with only partial overlap.

Stelzer AS, Maccioni L, Gerhold-Ay A, Smedby KE, Schumacher M, Nieters A, Binder H.

BMC Med Genet. 2019 Jul 19;20(1):128. doi: 10.1186/s12881-019-0849-0.

9.

Distribution of hospital care among pediatric and young adult Hodgkin lymphoma survivors-A population-based cohort study from Sweden and Denmark.

Glimelius I, Englund A, Rostgaard K, Smedby KE, Eloranta S, de Nully Brown P, Johansen C, Kamper P, Ljungman G, Hjalgrim LL, Hjalgrim H.

Cancer Med. 2019 Aug;8(10):4918-4927. doi: 10.1002/cam4.2363. Epub 2019 Jul 2.

10.

Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma.

Jain N, Hartert K, Tadros S, Fiskus W, Havranek O, Ma MCJ, Bouska A, Heavican T, Kumar D, Deng Q, Moore D, Pak C, Liu CL, Gentles AJ, Hartmann E, Kridel R, Smedby KE, Juliusson G, Rosenquist R, Gascoyne RD, Rosenwald A, Giancotti F, Neelapu SS, Westin J, Vose JM, Lunning MA, Greiner T, Rodig S, Iqbal J, Alizadeh AA, Davis RE, Bhalla K, Green MR.

Sci Transl Med. 2019 Jun 19;11(497). pii: eaav5599. doi: 10.1126/scitranslmed.aav5599.

11.

Author's reply to: A note on competing risks in analyses of cancer-specific mortality.

Benoni H, Smedby KE, Eloranta S.

Int J Cancer. 2019 Sep 15;145(6):1706-1707. doi: 10.1002/ijc.32517. Epub 2019 Jun 28. No abstract available.

PMID:
31209878
12.

Socioeconomic impact of Hodgkin lymphoma in adult patients: a systematic literature review.

Pálmarsdóttir R, Kiesbye Øvlisen A, Severinsen MT, Glimelius I, Smedby KE, El-Galaly T.

Leuk Lymphoma. 2019 Jun 6:1-16. doi: 10.1080/10428194.2019.1613538. [Epub ahead of print]

PMID:
31167589
13.

Mortality in adult-onset and elderly-onset IBD: a nationwide register-based cohort study 1964-2014.

Olén O, Askling J, Sachs MC, Neovius M, Smedby KE, Ekbom A, Ludvigsson JF.

Gut. 2019 May 15. pii: gutjnl-2018-317572. doi: 10.1136/gutjnl-2018-317572. [Epub ahead of print]

PMID:
31092591
14.

Survival among solid organ transplant recipients diagnosed with cancer compared to nontransplanted cancer patients-A nationwide study.

Benoni H, Eloranta S, Ekbom A, Wilczek H, Smedby KE.

Int J Cancer. 2020 Feb 1;146(3):682-691. doi: 10.1002/ijc.32299. Epub 2019 Apr 11.

PMID:
30919451
15.

Effects of Childhood-onset Inflammatory Bowel Disease on School Performance: A Nationwide Population-based Cohort Study Using Swedish Health and Educational Registers.

Malmborg P, Mouratidou N, Sachs MC, Hammar U, Khalili H, Neovius M, Hjern A, Smedby KE, Ekbom A, Askling J, Ludvigsson JF, Olén O.

Inflamm Bowel Dis. 2019 Mar 27. pii: izz040. doi: 10.1093/ibd/izz040. [Epub ahead of print]

PMID:
30916332
16.

Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas.

Ellin F, Maurer MJ, Srour L, Farooq U, Jerkeman M, Connors JM, Smedby KE, Bennani NN, Ansell SM, Slack GW, Cerhan JR, Relander T, Feldman AL, Savage KJ.

Br J Haematol. 2019 Aug;186(3):e24-e27. doi: 10.1111/bjh.15859. Epub 2019 Mar 11. No abstract available.

PMID:
30859549
17.

Reply to M. Sorigue et al.

Lockmer S, Østenstad B, Hagberg H, Holte H, Wahlin BE, Wader KF, Smedby KE, Brown P, Kimby E.

J Clin Oncol. 2019 Mar 20;37(9):759-760. doi: 10.1200/JCO.18.02362. Epub 2019 Feb 8. No abstract available.

PMID:
30735430
18.

Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma: A Nordic Lymphoma Epidemiology Group Study.

Biccler JL, Glimelius I, Eloranta S, Smeland KB, Brown PN, Jakobsen LH, Frederiksen H, Jerkeman M, Fosså A, Andersson TML, Holte H, Bøgsted M, El-Galaly TC, Smedby KE.

J Clin Oncol. 2019 Mar 20;37(9):703-713. doi: 10.1200/JCO.18.01652. Epub 2019 Feb 6.

PMID:
30726176
19.

Temporal trends in treatment-related incidence of diseases of the circulatory system among Hodgkin lymphoma patients.

Weibull CE, Björkholm M, Glimelius I, Lambert PC, Andersson TML, Smedby KE, Dickman PW, Eloranta S.

Int J Cancer. 2019 Sep 1;145(5):1200-1208. doi: 10.1002/ijc.32142. Epub 2019 Feb 5.

PMID:
30666628
20.

Optimizing Outcome Prediction in Diffuse Large B-Cell Lymphoma by Use of Machine Learning and Nationwide Lymphoma Registries: A Nordic Lymphoma Group Study.

Biccler JL, Eloranta S, de Nully Brown P, Frederiksen H, Jerkeman M, Jørgensen J, Jakobsen LH, Smedby KE, Bøgsted M, El-Galaly TC.

JCO Clin Cancer Inform. 2018 Dec;2:1-13. doi: 10.1200/CCI.18.00025.

21.

Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology.

Went M, Sud A, Speedy H, Sunter NJ, Försti A, Law PJ, Johnson DC, Mirabella F, Holroyd A, Li N, Orlando G, Weinhold N, van Duin M, Chen B, Mitchell JS, Mansouri L, Juliusson G, Smedby KE, Jayne S, Majid A, Dearden C, Allsup DJ, Bailey JR, Pratt G, Pepper C, Fegan C, Rosenquist R, Kuiper R, Stephens OW, Bertsch U, Broderick P, Einsele H, Gregory WM, Hillengass J, Hoffmann P, Jackson GH, Jöckel KH, Nickel J, Nöthen MM, da Silva Filho MI, Thomsen H, Walker BA, Broyl A, Davies FE, Hansson M, Goldschmidt H, Dyer MJS, Kaiser M, Sonneveld P, Morgan GJ, Hemminki K, Nilsson B, Catovsky D, Allan JM, Houlston RS.

Blood Cancer J. 2018 Dec 21;9(1):1. doi: 10.1038/s41408-018-0162-8.

22.

High tumour plasma cell infiltration reflects an important microenvironmental component in classic Hodgkin lymphoma linked to presence of B-symptoms.

Gholiha AR, Hollander P, Hedstrom G, Sundstrom C, Molin D, Smedby KE, Hjalgrim H, Glimelius I, Amini RM, Enblad G.

Br J Haematol. 2019 Jan;184(2):192-201. doi: 10.1111/bjh.15703. Epub 2018 Dec 2.

PMID:
30506671
23.

No association between low-dose aspirin use and breast cancer outcomes overall: a Swedish population-based study.

Frisk G, Ekberg S, Lidbrink E, Eloranta S, Sund M, Fredriksson I, Lambe M, Smedby KE.

Breast Cancer Res. 2018 Nov 20;20(1):142. doi: 10.1186/s13058-018-1065-0.

24.

Comparison of patients with and without pre-existing lymphoma at diagnosis of primary Sjögren's syndrome.

Vasaitis L, Nordmark G, Theander E, Backlin C, Smedby KE, Askling J, Rönnblom L, Sundström C, Baecklund E.

Scand J Rheumatol. 2019 May;48(3):207-212. doi: 10.1080/03009742.2018.1523456. Epub 2018 Nov 13.

PMID:
30422723
25.

Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B-cell lymphoma: a Swedish lymphoma register study.

Wästerlid T, Mohammadi M, Smedby KE, Glimelius I, Jerkeman M, Bottai M, Eloranta S.

J Intern Med. 2019 Apr;285(4):455-468. doi: 10.1111/joim.12849. Epub 2018 Nov 8.

PMID:
30368947
26.

Increased Mortality of Patients With Childhood-Onset Inflammatory Bowel Diseases, Compared With the General Population.

Olén O, Askling J, Sachs MC, Frumento P, Neovius M, Smedby KE, Ekbom A, Malmborg P, Ludvigsson JF.

Gastroenterology. 2019 Feb;156(3):614-622. doi: 10.1053/j.gastro.2018.10.028. Epub 2018 Oct 17.

PMID:
30342031
27.

Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia.

McMaster ML, Berndt SI, Zhang J, Slager SL, Li SA, Vajdic CM, Smedby KE, Yan H, Birmann BM, Brown EE, Smith A, Kleinstern G, Fansler MM, Mayr C, Zhu B, Chung CC, Park JH, Burdette L, Hicks BD, Hutchinson A, Teras LR, Adami HO, Bracci PM, McKay J, Monnereau A, Link BK, Vermeulen RCH, Ansell SM, Maria A, Diver WR, Melbye M, Ojesina AI, Kraft P, Boffetta P, Clavel J, Giovannucci E, Besson CM, Canzian F, Travis RC, Vineis P, Weiderpass E, Montalvan R, Wang Z, Yeager M, Becker N, Benavente Y, Brennan P, Foretova L, Maynadie M, Nieters A, de Sanjose S, Staines A, Conde L, Riby J, Glimelius B, Hjalgrim H, Pradhan N, Feldman AL, Novak AJ, Lawrence C, Bassig BA, Lan Q, Zheng T, North KE, Tinker LF, Cozen W, Severson RK, Hofmann JN, Zhang Y, Jackson RD, Morton LM, Purdue MP, Chatterjee N, Offit K, Cerhan JR, Chanock SJ, Rothman N, Vijai J, Goldin LR, Skibola CF, Caporaso NE.

Nat Commun. 2018 Oct 10;9(1):4182. doi: 10.1038/s41467-018-06541-2.

28.

Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up.

Lockmer S, Østenstad B, Hagberg H, Holte H, Johansson AS, Wahlin BE, Wader KF, Steen CB, Meyer P, Maisenhølder M, Smedby KE, Brown P, Kimby E.

J Clin Oncol. 2018 Oct 4:JCO1800262. doi: 10.1200/JCO.18.00262. [Epub ahead of print]

PMID:
30285560
29.

Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia.

Baliakas P, Moysiadis T, Hadzidimitriou A, Xochelli A, Jeromin S, Agathangelidis A, Mattsson M, Sutton LA, Minga E, Scarfò L, Rossi D, Davis Z, Villamor N, Parker H, Kotaskova J, Stalika E, Plevova K, Mansouri L, Cortese D, Navarro A, Delgado J, Larrayoz M, Young E, Anagnostopoulos A, Smedby KE, Juliusson G, Sheehy O, Catherwood M, Strefford JC, Stavroyianni N, Belessi C, Pospisilova S, Oscier D, Gaidano G, Campo E, Haferlach C, Ghia P, Rosenquist R, Stamatopoulos K; European Research Initiative on CLL (ERIC).

Haematologica. 2019 Feb;104(2):360-369. doi: 10.3324/haematol.2018.195032. Epub 2018 Sep 27.

30.

Contemporarily Treated Patients With Hodgkin Lymphoma Have Childbearing Potential in Line With Matched Comparators.

Weibull CE, Johansson ALV, Eloranta S, Smedby KE, Björkholm M, Lambert PC, Dickman PW, Glimelius I.

J Clin Oncol. 2018 Sep 10;36(26):2718-2725. doi: 10.1200/JCO.2018.78.3514. Epub 2018 Jul 25.

PMID:
30044694
31.

Real-world evidence in safety assessment of new treatments.

Smedby KE, Eloranta S.

Lancet Haematol. 2018 Nov;5(11):e510-e511. doi: 10.1016/S2352-3026(18)30073-5. Epub 2018 Jun 12. No abstract available.

PMID:
29907549
32.

Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Population-based Study.

Wästerlid T, Biccler JL, Brown PN, Bøgsted M, Enblad G, Mészáros Jørgensen J, Christensen JH, Wahlin BE, Smedby KE, El-Galaly TC, Jerkeman M.

Ann Oncol. 2018 Aug 1;29(8):1882-1883. doi: 10.1093/annonc/mdy184. No abstract available.

PMID:
29790897
33.

Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large B-cell lymphoma.

Ekberg S, Jerkeman M, Andersson PO, Enblad G, Wahlin BE, Hasselblom S, Andersson TM, Eloranta S, Smedby KE.

Am J Hematol. 2018 May 17. doi: 10.1002/ajh.25147. [Epub ahead of print]

34.

HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes.

Wang SS, Carrington M, Berndt SI, Slager SL, Bracci PM, Voutsinas J, Cerhan JR, Smedby KE, Hjalgrim H, Vijai J, Morton LM, Vermeulen R, Paltiel O, Vajdic CM, Linet MS, Nieters A, de Sanjose S, Cozen W, Brown EE, Turner J, Spinelli JJ, Zheng T, Birmann BM, Flowers CR, Becker N, Holly EA, Kane E, Weisenburger D, Maynadie M, Cocco P, Albanes D, Weinstein SJ, Teras LR, Diver WR, Lax SJ, Travis RC, Kaaks R, Riboli E, Benavente Y, Brennan P, McKay J, Delfau-Larue MH, Link BK, Magnani C, Ennas MG, Latte G, Feldman AL, Doo NW, Giles GG, Southey MC, Milne RL, Offit K, Musinsky J, Arslan AA, Purdue MP, Adami HO, Melbye M, Glimelius B, Conde L, Camp NJ, Glenn M, Curtin K, Clavel J, Monnereau A, Cox DG, Ghesquières H, Salles G, Bofetta P, Foretova L, Staines A, Davis S, Severson RK, Lan Q, Brooks-Wilson A, Smith MT, Roman E, Kricker A, Zhang Y, Kraft P, Chanock SJ, Rothman N, Hartge P, Skibola CF.

Cancer Res. 2018 Jul 15;78(14):4086-4096. doi: 10.1158/0008-5472.CAN-17-2900. Epub 2018 May 7.

35.

Greater attention should be paid to developing therapies for elderly patients with Hodgkin lymphoma-A population-based study from Sweden.

Björkholm M, Weibull CE, Eloranta S, Smedby KE, Glimelius I, Dickman PW.

Eur J Haematol. 2018 Jul;101(1):106-114. doi: 10.1111/ejh.13090. Epub 2018 May 23.

PMID:
29727497
36.

Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis.

Kleinstern G, Camp NJ, Goldin LR, Vachon CM, Vajdic CM, de Sanjose S, Weinberg JB, Benavente Y, Casabonne D, Liebow M, Nieters A, Hjalgrim H, Melbye M, Glimelius B, Adami HO, Boffetta P, Brennan P, Maynadie M, McKay J, Cocco PL, Shanafelt TD, Call TG, Norman AD, Hanson C, Robinson D, Chaffee KG, Brooks-Wilson AR, Monnereau A, Clavel J, Glenn M, Curtin K, Conde L, Bracci PM, Morton LM, Cozen W, Severson RK, Chanock SJ, Spinelli JJ, Johnston JB, Rothman N, Skibola CF, Leis JF, Kay NE, Smedby KE, Berndt SI, Cerhan JR, Caporaso N, Slager SL.

Blood. 2018 Jun 7;131(23):2541-2551. doi: 10.1182/blood-2017-11-814608. Epub 2018 Apr 19.

37.

A genome-wide association study of IgM antibody against phosphorylcholine: shared genetics and phenotypic relationship to chronic lymphocytic leukemia.

Chen X, Gustafsson S, Whitington T, Borné Y, Lorentzen E, Sun J, Almgren P, Su J, Karlsson R, Song J, Lu Y, Zhan Y, Hägg S, Svensson P, Smedby KE, Slager SL, Ingelsson E, Lindgren CM, Morris AP, Melander O, Karlsson T, de Faire U, Caidahl K, Engström G, Lind L, Karlsson MCI, Pedersen NL, Frostegård J, Magnusson PKE.

Hum Mol Genet. 2018 May 15;27(10):1809-1818. doi: 10.1093/hmg/ddy094.

PMID:
29547969
38.

Anti-cyclic citrullinated peptide antibodies, other common autoantibodies, and smoking as risk factors for lymphoma in patients with rheumatoid arthritis.

Baecklund E, Backlin C, Rönnelid J, Toes R, Huizinga T, Åhlin E, Askling J, Hochberg FH, Klareskog L, Kay J, Smedby KE.

Scand J Rheumatol. 2018 Jul;47(4):270-275. doi: 10.1080/03009742.2017.1376108. Epub 2018 Jan 16.

PMID:
29336646
39.

Short- and long-term risks of cardiovascular disease following radiotherapy in rectal cancer in four randomized controlled trials and a population-based register.

Chen L, Eloranta S, Martling A, Glimelius I, Neovius M, Glimelius B, Smedby KE.

Radiother Oncol. 2018 Mar;126(3):424-430. doi: 10.1016/j.radonc.2017.12.008. Epub 2018 Jan 3.

PMID:
29306497
40.

High proportions of PD-1+ and PD-L1+ leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcome.

Hollander P, Kamper P, Smedby KE, Enblad G, Ludvigsen M, Mortensen J, Amini RM, Hamilton-Dutoit S, d'Amore F, Molin D, Glimelius I.

Blood Adv. 2017 Aug 8;1(18):1427-1439. doi: 10.1182/bloodadvances.2017006346. eCollection 2017 Aug 8.

41.

No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy.

Baliakas P, Mattsson M, Hadzidimitriou A, Minga E, Agathangelidis A, Sutton LA, Scarfo L, Davis Z, Yan XJ, Plevova K, Sandberg Y, Vojdeman FJ, Tzenou T, Chu CC, Veronese S, Mansouri L, Smedby KE, Giudicelli V, Nguyen-Khac F, Panagiotidis P, Juliusson G, Anagnostopoulos A, Lefranc MP, Trentin L, Catherwood M, Montillo M, Niemann CU, Langerak AW, Pospisilova S, Stavroyianni N, Chiorazzi N, Oscier D, Jelinek DF, Shanafelt T, Darzentas N, Belessi C, Davi F, Ghia P, Rosenquist R, Stamatopoulos K.

Haematologica. 2018 Apr;103(4):e158-e161. doi: 10.3324/haematol.2017.182634. Epub 2017 Dec 21. No abstract available.

42.

Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma: a critical assessment of the R-IPI, IPI, and NCCN-IPI.

Biccler J, Eloranta S, de Nully Brown P, Frederiksen H, Jerkeman M, Smedby KE, Bøgsted M, El-Galaly TC.

Cancer Med. 2018 Jan;7(1):114-122. doi: 10.1002/cam4.1271. Epub 2017 Dec 13. Erratum in: Cancer Med. 2018 Apr;7(4):1572.

43.

Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma.

Bernatsky S, Velásquez García HA, Spinelli JJ, Gaffney P, Smedby KE, Ramsey-Goldman R, Wang SS, Adami HO, Albanes D, Angelucci E, Ansell SM, Asmann YW, Becker N, Benavente Y, Berndt SI, Bertrand KA, Birmann BM, Boeing H, Boffetta P, Bracci PM, Brennan P, Brooks-Wilson AR, Cerhan JR, Chanock SJ, Clavel J, Conde L, Cotenbader KH, Cox DG, Cozen W, Crouch S, De Roos AJ, de Sanjose S, Di Lollo S, Diver WR, Dogan A, Foretova L, Ghesquières H, Giles GG, Glimelius B, Habermann TM, Haioun C, Hartge P, Hjalgrim H, Holford TR, Holly EA, Jackson RD, Kaaks R, Kane E, Kelly RS, Klein RJ, Kraft P, Kricker A, Lan Q, Lawrence C, Liebow M, Lightfoot T, Link BK, Maynadie M, McKay J, Melbye M, Molina TJ, Monnereau A, Morton LM, Nieters A, North KE, Novak AJ, Offit K, Purdue MP, Rais M, Riby J, Roman E, Rothman N, Salles G, Severi G, Severson RK, Skibola CF, Slager SL, Smith A, Smith MT, Southey MC, Staines A, Teras LR, Thompson CA, Tilly H, Tinker LF, Tjonneland A, Turner J, Vajdic CM, Vermeulen RCH, Vijai J, Vineis P, Virtamo J, Wang Z, Weinstein S, Witzig TE, Zelenetz A, Zeleniuch-Jacquotte A, Zhang Y, Zheng T, Zucca M, Clarke AE.

Lupus Sci Med. 2017 Nov 12;4(1):e000187. doi: 10.1136/lupus-2016-000187. eCollection 2017.

44.

Parental Age and Risk of Lymphoid Neoplasms.

Larfors G, Glimelius I, Eloranta S, Smedby KE.

Am J Epidemiol. 2017 Nov 15;186(10):1159-1167. doi: 10.1093/aje/kwx185.

PMID:
29149251
45.

International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma.

Maurer MJ, Ellin F, Srour L, Jerkeman M, Bennani NN, Connors JM, Slack GW, Smedby KE, Ansell SM, Link BK, Cerhan JR, Relander T, Savage KJ, Feldman AL.

J Clin Oncol. 2017 Dec 20;35(36):4019-4026. doi: 10.1200/JCO.2017.73.8195. Epub 2017 Oct 26.

46.

An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome.

Hollander P, Rostgaard K, Smedby KE, Molin D, Loskog A, de Nully Brown P, Enblad G, Amini RM, Hjalgrim H, Glimelius I.

Eur J Haematol. 2018 Jan;100(1):88-97. doi: 10.1111/ejh.12987. Epub 2017 Nov 14.

PMID:
29064587
47.

Introduction to the symposium 'Targeted therapy in B-cell malignancies'.

Smedby KE, Rosenquist R.

J Intern Med. 2017 Nov;282(5):358-359. doi: 10.1111/joim.12685. No abstract available.

48.

Surgical Treatment in Childhood-onset Inflammatory Bowel Disease-A Nationwide Register-based Study of 4695 Incident Patients in Sweden 2002-2014.

Nordenvall C, Rosvall O, Bottai M, Everhov ÅH, Malmborg P, Smedby KE, Ekbom A, Askling J, Ludvigsson JF, Myrelid P, Olén O.

J Crohns Colitis. 2018 Jan 24;12(2):157-166. doi: 10.1093/ecco-jcc/jjx132.

PMID:
29029152
49.

Childhood onset inflammatory bowel disease and risk of cancer: a Swedish nationwide cohort study 1964-2014.

Olén O, Askling J, Sachs MC, Frumento P, Neovius M, Smedby KE, Ekbom A, Malmborg P, Ludvigsson JF.

BMJ. 2017 Sep 20;358:j3951. doi: 10.1136/bmj.j3951.

50.

The aetiology of B-cell lymphoid malignancies with a focus on chronic inflammation and infections.

Smedby KE, Ponzoni M.

J Intern Med. 2017 Nov;282(5):360-370. doi: 10.1111/joim.12684. Epub 2017 Sep 27. Review.

Supplemental Content

Loading ...
Support Center